Needham & Company LLC Cuts Cellebrite DI (NASDAQ:CLBT) Price Target to $15.00

Posted by Geri Gentry on May 15th, 2026

Cellebrite DI (NASDAQ:CLBT – Get Free Report) had its target price reduced by equities research analysts at Needham & Company LLC from $18.00 to $15.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price target indicates a potential upside of 14.33% from the company’s current price.

Separately, Wall Street Zen upgraded Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $21.75.

Read Our Latest Analysis on Cellebrite DI

Cellebrite DI Stock Up 8.4%

Shares of CLBT opened at $13.12 on Friday. The company has a 50-day moving average price of $13.56 and a two-hundred day moving average price of $15.55. The stock has a market cap of $3.27 billion, a price-to-earnings ratio of 42.32, a P/E/G ratio of 1.85 and a beta of 1.15. Cellebrite DI has a 12 month low of $11.02 and a 12 month high of $19.98.

Cellebrite DI (NASDAQ:CLBT – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.01. The company had revenue of $128.30 million for the quarter, compared to analyst estimates of $127.01 million. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The company’s revenue was up 19.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.10 EPS. Equities research analysts expect that Cellebrite DI will post 0.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Voss Capital LP grew its position in Cellebrite DI by 18.9% during the 4th quarter. Voss Capital LP now owns 8,050,000 shares of the company’s stock worth $145,142,000 after acquiring an additional 1,277,300 shares during the last quarter. Pertento Partners LLP raised its position in Cellebrite DI by 28.2% in the 4th quarter. Pertento Partners LLP now owns 5,959,324 shares of the company’s stock valued at $107,447,000 after purchasing an additional 1,311,109 shares during the last quarter. Invesco Ltd. raised its position in Cellebrite DI by 0.8% in the 4th quarter. Invesco Ltd. now owns 5,603,237 shares of the company’s stock valued at $101,026,000 after purchasing an additional 43,041 shares during the last quarter. Granahan Investment Management LLC boosted its stake in Cellebrite DI by 16.3% in the fourth quarter. Granahan Investment Management LLC now owns 3,057,018 shares of the company’s stock worth $55,118,000 after purchasing an additional 427,719 shares in the last quarter. Finally, Cooper Creek Partners Management LLC bought a new stake in shares of Cellebrite DI during the third quarter worth $55,999,000. Institutional investors own 45.88% of the company’s stock.

Trending Headlines about Cellebrite DI

Here are the key news stories impacting Cellebrite DI this week:

Positive Sentiment: Cellebrite reported Q1 2026 EPS of $0.12, ahead of the $0.11 consensus, while revenue of $128.3 million also topped estimates and climbed 19.3% year over year. View Press Release
Positive Sentiment: The company said first-quarter ARR growth was 21% and free cash flow margin reached 32%, signaling healthy recurring revenue and profitability trends. Cellebrite Announces First-Quarter 2026 Results
Positive Sentiment: Cellebrite outlined Q2 ARR guidance of $510 million to $513 million and said early access to its Genesis product has reached more than 500 users, reinforcing adoption of its AI-driven offerings. Seeking Alpha article
Neutral Sentiment: Two executives, CRO Marcus Jewell and CMO David Nicholas Gee, disclosed small insider stock sales, though the transactions were minor relative to their overall holdings.
Negative Sentiment: Management’s Q2 revenue outlook of $130 million to $133 million came in below the $134.9 million consensus, and FY 2026 revenue guidance of $565 million to $571 million was also slightly below estimates, which may be weighing on the stock. Cellebrite Announces First-Quarter 2026 Results

About Cellebrite DI

(Get Free Report)

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.